Accessibility Menu
ImmuCell Stock Quote

ImmuCell (NASDAQ: ICCC)

$5.40
(-10.7%)
-0.65
Price as of November 14, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$5.40
Daily Change
(-10.7%) $0.65
Day's Range
$5.40 - $5.61
Previous Close
$5.40
Open
$5.55
Beta
0.24
Volume
50,297
Average Volume
15,945
Market Cap
48.8M
Market Cap / Employee
$5.40M
52wk Range
$3.40 - $7.60
Revenue
-
Gross Margin
0.41%
Dividend Yield
N/A
EPS
$0.26
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

ImmuCell Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
ICCC+50%-6.09%-1.25%+440%
S&P+13.19%+87.83%+13.42%+1,532%

ImmuCell Company Info

ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. Its products include first defense for scours, California mastitis test kits, and purified nisin intramammary treatment for mastitis. The company was founded in 1982 and is headquartered in Portland, ME.

News & Analysis

Financial Health

General

Q3 2025YOY Change
Revenue$5.51M-8.4%
Gross Profit$2.36M49.2%
Gross Margin42.92%16.6%
Market Cap$56.54M98.8%
Market Cap / Employee$0.75M0.0%
Employees75-5.1%
Net Income-$0.14M80.1%
EBITDA$0.70M597.6%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q3 2025YOY Change
Net Cash$3.89M2.0%
Accounts Receivable$2.55M10.7%
Inventory9.831.4%

Liabilities

Q3 2025YOY Change
Long Term Debt$11.93M-12.1%
Short Term Debt$1.67M-14.6%

Ratios

Q3 2025YOY Change
Return On Assets5.15%13.7%
Return On Invested Capital-5.74%-0.3%

Cash Flow

Q3 2025YOY Change
Free Cash Flow-$1.78M-144.1%
Operating Free Cash Flow-$1.18M-85.0%

Valuation

MetricQ2 2025Q3 2025YoY Change
Price to Earnings36.9424.14-
Price to Book1.721.562.161.8956.14%
Price to Sales1.741.582.222.0463.76%
Price to Tangible Book Value1.731.572.161.9055.87%
Price to Free Cash Flow TTM54.5335.6379.03-
Enterprise Value to EBITDA43.8829.5957.4694.76-77.04%
Free Cash Flow Yield1.8%2.8%1.3%-
Return on Equity-8.2%-1.0%6.6%8.3%-156.87%
Total Debt$15.10M$14.66M$14.27M$13.61M-12.41%

No results found

No podcast episodes available.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.